Highlights of This Issue 2271

SMALL MOLECULE THERAPEUTICS

2273 Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Ping Chen, Nathan V. Lee, Wenxue Hu, Meirong Xu, Rose Ann Ferre, Hi Eu Lam, Simon Bergqvist, James Solowiej, Wade Diehl, You-Ai He, Xi Yu, Asako Nagata, Todd VanArsdale, and Brion W. Murray

2282 Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform
Yilin Zhang, Shravan Kumar Sriraman, Hilary A. Kenny, Ed Luther, Vladimir Torchilin, and Ernst Lengyel

2294 A Novel Small Molecule Activator of Nuclear Receptor SHP Inhibits HCC Cell Migration via Suppressing Ccl2
Zhihong Yang, Angela N. Koehler, and Li Wang

2302 Mechanism-Based Drug Combinations with the DNA Strand–Breaking Nucleoside Analog CNDAC
Xiaojun Liu, Yingjun Jiang, Billie Nowak, Sarah Hargis, and William Plunkett

2314 Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo
Barbara A. Helfrich, Ji Hyo Kim, Desiang Gao, Daniel C. Chan, Zhiyong Zhang, Aik-Choon Tan, and Paul A. Bunn Jr

2323 BPR11373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT–Driven Myeloid Leukemia
Li-Tzong Chen, Chiung-Tong Chen, Weir-Torn Jiaang, Tsai-Yun Chen, Joseph H. Butterfield, Neng-Yao Shih, John Tsu-An Hsu, Hui-You Lin, Sheng-Fung Lin, and Hui-Jen Tsai

2334 Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Maximilien Murone, Anne Vasilin Chessex, Antoine Attinger, Raghuveer Ramachandra, Shankar J. Shetty, Girish Daginakatte, Saumitra Sengupta, Sivapriya Marappan, Samiulla Dhodheri, Stefania Rigotti, Yogeshwar Bachhav, Silvano Brienza, Peter Traxler, Marc Lang, Michel Aguer, Vincent Zoret, Olivier Michielin, Courtney Nicholas, Faye M. Johnson, Murali Ramachandra, and Andres McAllister

2344 Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
Michele C. Smith, Mary M. Mader, James A. Cook, Philip Iversen, Rose Ajamie, Everett Perkins, Laura Bloem, Yvonne Y. Yip, David A. Banda, Philip P. Waid, Douglas J. Zuckner, Debra A. Young, Manuel Sanchez-Felix, Gregory P. Donoho, and Volker Wacheck

2357 Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro
Mir A. Hoda, Christine Pinker, Yawen Dong, Karin Schelch, Petra Heffener, Kushtrim Kyeziu, Sushilla van Schoonhoven, Thomas Klikovits, Viktoria Laszlo, Anita Rozsas, Judit Ozsvar, Walter Klepetko, Balazs Dobre, Michael Grusch, Balazs Hagedus, and Walter Berger

2370 Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study
Arthur Winer, Maxwell Janosky, Beth Harrison, Judy Zhong, Dariusz Moussai, Pinar Sivath, Nina Schatz-Siemers, Jennifer Zeng, Sylvia Adams, and Paola Mignatti

2378 Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic–Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104
James W.T. Yates, Susan Ashton, Darren Cross, Martine J. Mellor, Stew J. Powell, and Peter Ballard

2388 Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases

2399 Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
Gema Santamaria Nufiez, Carlos Mario Genes Robles, Christophe Giraudon, Juan Fernandez Martinez-Leal, Emmanuel Compe, Frederic Coin, Pablo Aviles, Carlos Maria Salmarini, and Jean-Marc Egly
LARGE MOLECULE THERAPEUTICS

2413  **In Vivo Antitumor Activity of a Recombinant IL7/IL15 Hybrid Cytokine in Mice**
Yinhong Song, Yalan Liu, Rong Hu, Min Su, Debra Rood, and Laijun Lai

2422  **In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia**
Urs B. Hagemann, Katrine Wickstroem, Ellen Wang, Adam O. Shea, Kristine Sponheim, Jenny Karlsson, Timothy Harrison, Gerard G. Hanna, Karl T. Butterworth, Kevin M. Prise, and Daniel B. Longley

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

2432  **FLIP: A Targetable Mediator of Resistance to Radiation in Non–Small Cell Lung Cancer**

2442  **Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma**
Yong Qin, Jason Roszik, Chandrani Chattopadhyay, Yuuri Hashimoto, Chengwen Liu, Zachary A. Cooper, Jennifer A. Wargo, Patrick Hwu, Suhendan Ekmekcioglu, and Elizabeth A. Grimm

2455  **The Tyrosine Kinase Inhibitor Imatinib Augments Extracellular Fluid Exchange and Reduces Average Collagen Fibril Diameter in Experimental Carcinoma**
P. Olof Olsson, Renata Gustafsson, René in’t Zandt, Tomas Friman, Marco Maccarana, Emil Tykesson, Åke Oldberg, Kristofer Rubin, and Sebastian Kalamajski

2465  **FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model**
Cécile Gostaler, Isabelle Ader, and Olivier Cuvillier

2475  **TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics**

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

2486  **EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer**

2498  **Genomic Landscape of Malignant Mesotheliomas**
Shumei Kato, Brett N. Tomson, Timon P.H. Buys, Sheryl K. Elkin, Jennifer L. Carter, and Razelle Kurzrock

2508  **Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment**
Xiaoxiao Sun, Qiaoling Song, Li He, Lei Yan, Jingli Liu, Qing Zhang, and Qiang Yu

MODELS AND TECHNOLOGIES

2521  **Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma**
Qingling Huang, Valentina E. Schneeberger, Noreen Luetetke, Chenglu Jin, Roha Azfal, Mikalai M. Budzdevich, Rilesh J. Makanji, Gary V. Martinez, Tao Shen, Lichao Zhao, Kar-Ming Fung, Eric B. Haura, Domenico Coppola, and Jie Wu

2530  **Biodistribution and Targeting of Anti-ST4 Antibody–Drug Conjugate Using Fluorescence Molecular Tomography**
Anand Giddabasappa, Vijay R. Gupta, Rand Norberg, Parul Gupta, Mary E. Spijker, Joann Venlind, Brian Rago, Jeetendra Eswaraka, Mauricio Leal, and Puja Sapra

2541  **Development and Application of a Novel Model System to Study “Active” and “Passive” Tumor Targeting**
Amarnath Mukherjee, Binod Kumar, Koji Hatano, Luisa M. Russell, Bruce J. Trock, Peter C. Seardon, Alan K. Meeker, Martin G. Pomper, and Shawn E. Lupold

**AC icon indicates Author Choice**
For more information please visit www.aacrjournals.org
A liposomal platform encapsulating both the third generation P-gp inhibitor tariquidar and paclitaxel was developed to overcome paclitaxel resistance in ovarian cancer cells. Liposomal paclitaxel-treated cells had a diffuse pattern of β-tubulin expression (shown in green). Treatment with liposomal tariquidar/paclitaxel resulted in cell rounding and ring-like β-tubulin formations around the nucleus. The liposomal encapsulated tariquidar and paclitaxel synergistically inhibited cell viability, blocked proliferation, and caused G2–M arrest in paclitaxel-resistant ovarian cancer cell lines. For details, see the article by Zhang, Sriraman, and colleagues on page 2282.